Company intelligence / Profile preview

Rodin Therapeutics

Cambridge, Massachusetts, United Statesinvestor.alkermes.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Rodin developed highly selective small molecule inhibitors of specific HDAC complexes to modulate gene expression in the brain. Their approach aimed to restore synaptic function and resilience in neurodegenerative diseases. Preclinical studies demonstrated increased spine density, synaptic proteins, and improved long-term potentiation with promising safety profiles compared to older non-selective epigenetic drugs. No clinical trial results were reported before acquisition.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Proteros Biostructures AG (structural biology platform partnership/founding shareholder)

Beyond the preview

Go deeper on Rodin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rodin Therapeutics.

Explore the full profile